Novo Nordisk (NYSE: NVO) Stock Analysis: Downgrade, Price Target, and Future Outlook

Font: Financial Modeling Prep  • Sep 11, 2026

• Morgan Stanley downgraded Novo Nordisk (NYSE: NVO) to "Underweight," setting a price target of $40.00, implying a potential 9.11% downside from its then-current stock price of $44.01.
• The pharmaceutical giant's shares have recently underperformed, with a 1.23% daily decline and a 3.94% loss over the past month, lagging behind the broader market and the Medical sector.
• Despite a projected 21.57% decrease in Earnings Per Share (EPS) to $0.80 and a 2.35% revenue decline to $11.47 billion, Novo Nordisk saw positive news with its weight-loss drug Wegovy gaining approval in China, though valuation risks persist.

Novo Nordisk (NYSE: NVO) is a global pharmaceutical company known for its leadership in diabetes and obesity treatments. The company is a major player in the GLP-1 drug market, which includes popular medications like Wegovy. Novo Nordisk faces significant competition and regulatory risks, which are critical factors for its future performance.

On September 11, 2026, Morgan Stanley analyst Thibault Boutherin set a price target of $40.00 for Novo Nordisk. This target suggests a potential downside of about 9.11% from the stock's price of $44.01 at the time. The bank also downgraded its rating on the company to "Underweight," indicating a more cautious outlook for the pharmaceutical stock.

This bearish sentiment is reflected in Novo Nordisk's recent market activity. The stock recently closed at $44.01, a 1.23% decline that was larger than the losses seen in the S&P 500, Dow, and Nasdaq. Over the past month, Novo Nordisk shares have lost 3.94%, underperforming both the broader market and the Medical sector.

Looking forward, analysts anticipate challenges in the company's upcoming earnings report. As highlighted by Zacks Investment Research, Novo Nordisk is expected to report an Earnings Per Share (EPS) of $0.80, a 21.57% decrease from the prior year. Revenue is also projected to decline by 2.35% to $11.47 billion.

Despite the downgrade, Novo Nordisk has seen positive developments. The company's weight-loss drug, Wegovy, was approved in China for a liver disease, as reported by Reuters. An article from Seeking Alpha also notes a "Strong Buy" rating after a strong quarter but points to high valuation risks and challenges with competition in the GLP-1 market.